• Consensus Rating: Moderate Buy
  • Consensus Price Target: $80.23
  • Forecasted Upside: 9.32%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$73.39
▲ +0.95 (1.31%)

This chart shows the closing price for MET by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MetLife Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MET and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MET

Analyst Price Target is $80.23
▲ +9.32% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for MetLife in the last 3 months. The average price target is $80.23, with a high forecast of $86.00 and a low forecast of $71.00. The average price target represents a 9.32% upside from the last price of $73.39.

This chart shows the closing price for MET for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 investment analysts is to moderate buy stock in MetLife. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/10/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$82.00 ➝ $83.00Low
7/8/2024Keefe, Bruyette & WoodsLower TargetOutperform ➝ Outperform$86.00 ➝ $85.00Low
7/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$81.00 ➝ $86.00Low
6/28/2024Jefferies Financial GroupLower TargetBuy ➝ Buy$88.00 ➝ $83.00Low
5/22/2024ArgusBoost TargetBuy ➝ Buy$77.00 ➝ $80.00Low
5/10/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$86.00 ➝ $85.00Low
5/7/2024Keefe, Bruyette & WoodsLower TargetOutperform ➝ Outperform$87.00 ➝ $86.00Low
5/6/2024Piper SandlerLower TargetOverweight ➝ Overweight$85.00 ➝ $82.00Low
4/15/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$80.00 ➝ $82.00Low
4/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$83.00 ➝ $86.00Low
4/10/2024Keefe, Bruyette & WoodsBoost TargetOutperform ➝ Outperform$82.00 ➝ $87.00Low
4/5/2024Piper SandlerBoost TargetOverweight ➝ Overweight$74.00 ➝ $85.00Low
2/6/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$85.00 ➝ $83.00Low
2/5/2024UBS GroupLower TargetBuy ➝ Buy$87.00 ➝ $82.00Low
1/10/2024UBS GroupBoost TargetBuy ➝ Buy$84.00 ➝ $87.00Low
1/8/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$70.00 ➝ $80.00Low
12/7/2023Keefe, Bruyette & WoodsLower TargetOutperform ➝ Outperform$79.00 ➝ $77.00Low
11/17/2023BarclaysReiterated RatingOverweight$71.00Low
11/2/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$79.00 ➝ $80.00N/A
10/6/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$85.00 ➝ $82.00Low
10/4/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$71.00Low
9/13/2023Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00Low
8/18/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$78.00 ➝ $79.00Low
8/15/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$82.00 ➝ $83.00Low
8/14/2023ArgusBoost TargetBuy ➝ Buy$70.00 ➝ $77.00Low
8/9/2023CitigroupBoost TargetBuy ➝ Buy$76.00 ➝ $81.00Low
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$70.00 ➝ $74.00Low
8/3/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$78.00Low
5/26/2023Royal Bank of CanadaLower Target$68.00 ➝ $65.00Low
5/26/2023Wells Fargo & CompanyBoost Target$72.00 ➝ $75.00Low
4/20/2023Royal Bank of CanadaLower TargetOutperform$83.00 ➝ $76.00Low
4/12/2023Morgan StanleyLower TargetOverweight$90.00 ➝ $80.00Low
4/12/2023BarclaysLower TargetOverweight$83.00 ➝ $79.00Low
4/5/2023Piper SandlerLower TargetOverweight$82.00 ➝ $74.00Low
4/5/2023Wells Fargo & CompanyLower TargetOverweight$84.00 ➝ $72.00Low
4/5/2023The Goldman Sachs GroupLower TargetNeutral$79.00 ➝ $65.00Low
2/2/2023Morgan StanleyBoost TargetOverweight$88.00 ➝ $90.00Low
1/18/2023Wells Fargo & CompanyBoost TargetOverweight$81.00 ➝ $83.00Low
1/10/2023Morgan StanleyBoost TargetOverweight$87.00 ➝ $88.00Low
1/9/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$80.00 ➝ $78.00Low
1/6/2023JPMorgan Chase & Co.Boost TargetOverweight$77.00 ➝ $80.00Low
12/9/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$86.00 ➝ $82.00N/A
11/17/2022Morgan StanleyBoost TargetOverweight$85.00 ➝ $87.00Low
11/16/2022CitigroupBoost Target$77.00 ➝ $84.00Low
11/3/2022JPMorgan Chase & Co.Boost TargetOverweight$74.00 ➝ $77.00Low
11/3/2022Morgan StanleyBoost TargetOverweight$83.00 ➝ $85.00Low
10/12/2022Wells Fargo & CompanyLower TargetOverweight$75.00 ➝ $74.00Low
9/21/2022Raymond JamesInitiated CoverageMarket PerformLow
8/22/2022Credit Suisse GroupBoost TargetOutperform$68.00 ➝ $77.00Low
8/17/2022Morgan StanleyBoost TargetOverweight$79.00 ➝ $83.00Low
8/9/2022Evercore ISIBoost Target$81.00Low
8/4/2022Morgan StanleyBoost TargetOverweight$78.00 ➝ $79.00N/A
7/19/2022BarclaysSet Target$75.00Low
7/13/2022BarclaysLower TargetOverweight$79.00 ➝ $75.00N/A
7/11/2022JPMorgan Chase & Co.Lower Target$75.00 ➝ $74.00N/A
7/6/2022Evercore ISILower TargetOutperform$81.00 ➝ $80.00N/A
7/6/2022Morgan StanleyLower TargetOverweight$80.00 ➝ $78.00N/A
6/22/2022Wolfe ResearchUpgradeMarket Perform ➝ Outperform$70.00 ➝ $74.00Low
5/23/2022CitigroupInitiated CoverageBuy$77.00Low
4/12/2022BarclaysBoost TargetOverweight$76.00 ➝ $79.00Low
4/6/2022Piper SandlerBoost TargetOverweight$77.00 ➝ $80.00Medium
4/5/2022JPMorgan Chase & Co.Boost Target$69.00 ➝ $75.00N/A
2/22/2022Morgan StanleyBoost TargetOverweight$76.00 ➝ $79.00Medium
1/25/2022Jefferies Financial GroupInitiated CoverageBuy$74.00Low
1/21/2022Wolfe ResearchInitiated CoverageMarket Perform$70.00Low
1/12/2022UBS GroupBoost TargetBuy$74.00 ➝ $77.00Low
1/11/2022BarclaysBoost TargetOverweight$72.00 ➝ $75.00Low
1/7/2022Morgan StanleyBoost TargetOverweight$75.00 ➝ $76.00Low
1/5/2022Evercore ISIUpgradeIn-Line ➝ Outperform$67.00 ➝ $75.00High
1/4/2022Wells Fargo & CompanyLower TargetOverweight$75.00 ➝ $74.00Low
12/2/2021The Goldman Sachs GroupInitiated CoverageBuy$77.00Low
10/14/2021Morgan StanleyBoost TargetOverweight$74.00 ➝ $75.00Low
10/12/2021BarclaysBoost TargetOverweight$69.00 ➝ $72.00Low
8/5/2021Morgan StanleyBoost TargetOverweight$73.00 ➝ $74.00Low
7/15/2021Morgan StanleyBoost TargetOverweight$72.00 ➝ $73.00Low
5/13/2021Credit Suisse GroupBoost TargetOutperform$55.00 ➝ $68.00Medium
5/7/2021Royal Bank of CanadaBoost TargetOutperform$66.00 ➝ $74.00Low
5/6/2021Morgan StanleyBoost TargetOverweight$70.00 ➝ $72.00High
4/26/2021UBS GroupInitiated CoverageBuy$72.00N/A
4/20/2021UBS GroupInitiated CoverageBuy$72.00Medium
4/12/2021BarclaysBoost TargetOverweight$65.00 ➝ $69.00Low
4/5/2021JPMorgan Chase & Co.Boost TargetCautious ➝ Overweight$58.00 ➝ $64.00Low
4/1/2021Royal Bank of CanadaBoost Target$57.00 ➝ $66.00Low
4/1/2021Morgan StanleyBoost TargetOverweight$60.00 ➝ $70.00Low
3/31/2021CitigroupBoost Target$58.00 ➝ $69.00Low
2/25/2021Morgan StanleyBoost TargetOverweight$58.00 ➝ $60.00Medium
2/23/2021BarclaysBoost TargetOverweight$53.00 ➝ $60.00Low
2/17/2021ArgusBoost TargetPositive ➝ Buy$53.00 ➝ $63.00Low
2/4/2021Morgan StanleyBoost TargetOverweight$57.00 ➝ $58.00High
1/15/2021Morgan StanleyBoost TargetOverweight$53.00 ➝ $57.00Low
1/6/2021Piper SandlerUpgradeNeutral ➝ Overweight$45.00 ➝ $52.00N/A
12/13/2020BarclaysReiterated RatingBuy$53.00Medium
12/8/2020Smith Barney CitigroupUpgradeNeutral ➝ Buy$39.00 ➝ $55.00Low
12/4/2020The Goldman Sachs GroupInitiated CoverageNeutral$48.00Low
11/18/2020Morgan StanleyBoost TargetOverweight$49.00 ➝ $53.00Medium
11/17/2020Credit Suisse GroupBoost TargetOutperform ➝ Positive$46.00 ➝ $55.00Low
11/17/2020BarclaysInitiated CoverageOverweight$52.00Low
11/5/2020Morgan StanleyBoost TargetOverweight$47.00 ➝ $49.00High
10/6/2020Morgan StanleyBoost TargetOverweight$46.00 ➝ $47.00Medium
9/18/2020Credit Suisse GroupReiterated RatingBuy$46.00Low
8/20/2020Morgan StanleyBoost TargetOverweight$44.00 ➝ $46.00Low
8/19/2020ArgusReiterated RatingBuyLow
8/6/2020Wells Fargo & CompanyReiterated RatingBuy$45.00Medium
7/6/2020Morgan StanleyBoost TargetOverweight$40.00 ➝ $44.00Low
6/1/2020Bank of AmericaInitiated CoverageBuyLow
5/8/2020Royal Bank of CanadaBoost TargetOutperform$42.00 ➝ $44.00Medium
5/7/2020Morgan StanleyBoost TargetOverweight$38.00 ➝ $40.00Medium
4/27/2020Credit Suisse GroupLower TargetOutperform$60.00 ➝ $46.00Low
4/3/2020Piper SandlerLower TargetNeutral$38.00 ➝ $33.00Medium
4/1/2020Wells Fargo & CompanyLower TargetOverweight$59.00 ➝ $44.00Medium
3/20/2020Royal Bank of CanadaLower Target$57.00 ➝ $42.00High
3/17/2020Morgan StanleyLower TargetOverweight$60.00 ➝ $38.00High
3/16/2020CitigroupUpgradeSell ➝ Neutral$46.00 ➝ $32.00Medium
3/10/2020Piper SandlerLower TargetNeutral$51.00 ➝ $38.00Medium
2/27/2020Piper SandlerLower TargetNeutral$55.00 ➝ $51.00High
2/9/2020Royal Bank of CanadaReiterated RatingBuy$57.00Low
2/3/2020Credit Suisse GroupLower TargetOutperform$63.00 ➝ $60.00Low
1/7/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$55.00 ➝ $60.00Low
1/6/2020Wells Fargo & CompanyReiterated RatingBuyN/A
12/9/2019Wells Fargo & CompanyReiterated RatingBuyLow
10/15/2019B. RileyReiterated RatingNeutralMedium
10/10/2019UBS GroupBoost TargetNeutral$46.00 ➝ $47.00Low
9/13/2019CitigroupLower TargetSell$42.00 ➝ $41.00Low
8/20/2019Morgan StanleyLower TargetEqual Weight$54.00 ➝ $53.00Low
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 26 very positive mentions
  • 39 positive mentions
  • 19 negative mentions
  • 11 very negative mentions
12/17/2023
  • 26 very positive mentions
  • 69 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
1/16/2024
  • 39 very positive mentions
  • 68 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
2/15/2024
  • 40 very positive mentions
  • 40 positive mentions
  • 4 negative mentions
  • 13 very negative mentions
3/16/2024
  • 32 very positive mentions
  • 35 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/15/2024
  • 29 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
5/15/2024
  • 25 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024
  • 22 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 22 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
MetLife logo
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was incorporated in 1999 and is based in New York, New York.
Read More

Today's Range

Now: $73.39
Low: $72.44
High: $73.78

50 Day Range

MA: $71.15
Low: $68.55
High: $74.22

52 Week Range

Now: $73.39
Low: $57.70
High: $74.68

Volume

3,916,727 shs

Average Volume

3,023,406 shs

Market Capitalization

$52.19 billion

P/E Ratio

25.22

Dividend Yield

2.97%

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of MetLife?

The following Wall Street analysts have issued research reports on MetLife in the last twelve months: Argus, Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for MET.

What is the current price target for MetLife?

13 Wall Street analysts have set twelve-month price targets for MetLife in the last year. Their average twelve-month price target is $80.23, suggesting a possible upside of 9.3%. JPMorgan Chase & Co. has the highest price target set, predicting MET will reach $86.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $71.00 for MetLife in the next year.
View the latest price targets for MET.

What is the current consensus analyst rating for MetLife?

MetLife currently has 1 hold rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MET.

What other companies compete with MetLife?

How do I contact MetLife's investor relations team?

MetLife's physical mailing address is 200 PARK AVENUE, NEW YORK NY, 10166. The financial services provider's listed phone number is (212) 578-9500 and its investor relations email address is [email protected]. The official website for MetLife is www.metlife.com. Learn More about contacing MetLife investor relations.